A key goal for optimising brand uptake is to demonstrate to customers the comparative positive impact of the brand on overall disease pathways outcomes and costs. The Res Comparative Value Impact Tool (CVIT) provides an online platform for achieving this through detailed mapping of disease pathway medicines (and other items such as diagnostics) to provide a baseline profile against which brand switching impact can be demonstrated. The CVIT package includes: